Pieris Pharmaceuticals, Inc.

NasdaqCM:PIRS Voorraadrapport

Marktkapitalisatie: US$22.8m

Pieris Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Pieris Pharmaceuticals is Steve Yoder, benoemd in Dec2014, heeft een ambtstermijn van 9.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.36M, bestaande uit 43% salaris en 57% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde $ 1.30K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 7 jaar.

Belangrijke informatie

Steve Yoder

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris43.0%
Dienstverband CEO9.9yrs
Eigendom CEO0.006%
Management gemiddelde ambtstermijn5.2yrs
Gemiddelde ambtstermijn bestuur7yrs

Recente managementupdates

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Analyse CEO-vergoeding

Hoe is Steve Yoder's beloning veranderd ten opzichte van Pieris Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$1mUS$585k

-US$25m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$2mUS$565k

-US$33m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$548k

-US$46m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$48m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$535k

-US$37m

Sep 30 2020n/an/a

-US$26m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$2mUS$515k

-US$28m

Sep 30 2019n/an/a

-US$36m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$3mUS$500k

-US$27m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017US$1mUS$450k

-US$18m

Compensatie versus markt: De totale vergoeding ($USD 1.36M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Steve Yoder (48 yo)

9.9yrs

Tenure

US$1,358,952

Compensatie

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Stephen Yoder
CEO, President & Director9.9yrsUS$1.36m0.0057%
$ 1.3k
Thomas Bures
Senior VP5.2yrsUS$729.04k0.018%
$ 4.2k
Maria Kelman
Executive Director of Investor Relationsno datageen gegevensgeen gegevens
Prompong Chaikul
Chief Supply Chain Officer5.1yrsgeen gegevensgeen gegevens

5.2yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PIRS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Stephen Yoder
CEO, President & Director9.9yrsUS$1.36m0.0057%
$ 1.3k
James Arthur Geraghty
Independent Chairman7.5yrsUS$94.09k0.019%
$ 4.3k
Michael Richman
Independent Director9.9yrsUS$52.09k0%
$ 0
Christopher Kiritsy
Independent Director8.2yrsUS$72.58k0.019%
$ 4.3k
Peter Kiener
Independent Director6.2yrsUS$65.08k0%
$ 0
Matthew Sherman
Independent Director6.1yrsUS$53.09k0%
$ 0
Ann Barbier
Independent Director6.6yrsUS$52.09k0%
$ 0
Maya Said
Independent Director5.3yrsUS$52.09k0%
$ 0
Ian Adcock
Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Oliver Eickelberg
Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Fan Chung
Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Peter Barnes
Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens

7.0yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PIRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).